Title: NAUGEN, Building Global Innovation Highways

Enterprise Name: NAUGEN, Inc.

Founder/CEO/Speaker: Jaehan Park (Physics 94; jpark@naugen.com)

About NAUGEN, Inc.

NAUGEN, Inc. is a *global innovation* accelerator dedicated to fostering Novel, Advanced, and Unprecedented (NAU) technologies to extend and enhance life for all humanity. By consulting and accelerating high-potential biotech and high-tech startups, NAUGEN collaborates with revolutionary innovators in science and technology, offering them comprehensive strategies and networks to fast-track growth and capitalization through special-purpose companies (SPCs).

NAUGEN's primary focus areas include oncology, infectious diseases, immunology, CNS, regenerative medicine, rare diseases, and medical/drug devices, along with the deep application of artificial intelligence and quantum computing. The company envisions advancing innovative ideas and businesses that benefit not only mainstream industries but also underprivileged communities in less-developed regions by addressing critical unmet medical needs, including neglected infectious diseases.

Currently, NAUGEN is driving innovations in the following areas and is open to collaboration, partnerships, and investments:

- 1. Al-powered T-cell therapeutics for oncology
- 2. First-in-class therapeutics for fibrotic diseases
- 3. Al-driven multi-omics biomarker-based drug discovery
- 4. Nature-inspired regenerative medicine to reverse aging
- 5. Al-augmented, self-powered smart medical wearables
- 6. Building an innovation ecosystem connecting the US, Korea, and India

About Jaehan Park

Jaehan Park is the founder and CEO of **NAUGEN, Inc.** and serves as a Mentor-in-Residence for **the Korea Innovation Center Washington DC** (KIC DC). With over two decades of experience, Jaehan has played pivotal roles in the growth and globalization of leading biotech and high-tech companies.

• Key Achievements:

- As Chief Strategy Officer at NeolmmuneTech, Inc., a public clinical-stage US biotech company, he contributed to the development of transformative cancer immunotherapeutics in collaboration with global pharmaceutical companies and prestigious universities and hospitals.
- At OncoPep, Inc., a private clinical-stage US biotech company, he supported the development of cancer vaccines in partnership with Dana-Farber Cancer Institute and Harvard Medical School.
- As Senior Manager at Genexine, Inc., a public clinical-stage South Korean biotech company, he drove the exponential growth of the leading South Korean biotech developing novel biologics and DNA vaccines across multiple therapeutic areas.
- At Accenture, Ltd., the world's largest management consulting firm, he consulted for tech giants like Samsung, LG, and SK, focusing on strategy and process innovation.

Global Contributions:

- Assisted the U.S. White House Coronavirus Task Force in sourcing medical countermeasures during the COVID-19 pandemic, working in coordination with the South Korean Embassy.
- Facilitating collaborations between BARDA (Biomedical Advanced Research and Development Authority) under the U.S. Department of Health and Human Services (HHS) and the Office of the Prime Minister of South Korea to strengthen pandemic preparedness and response efforts.

Strengths and Expertise:

 Jaehan excels in designing growth strategies and execution plans, combining business acumen with deep scientific knowledge. He also has an extensive international network and expertise in business development, particularly in healthcare, biotech, MedTech, and IT+BT convergence.

Education:

- o B.S. in Physics, Seoul National University
- Master of Engineering in Biotechnology, Yonsei University Graduate School of Engineering



NAUGEN identifies revolutionary innovations across the world, while the market has not yet recognized their potential value



NAUGEN, a global innovation accelerator incubates

Novel·∧dvanced · Unprecedented

Products and technology

